HVIVO PLC (HVO) — Full Year Results

Investor webinar replay

Replay transcript excerpt

Good evening, ladies and gentlemen, and welcome to the HVIVO PLC Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged. They can be submitted at any time via the Q and A tab that's just situated on the right hand corner of your screen. Please just simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and will publish those responses where it's appropriate to do so on the Investor Meet company platform. And before we begin, as usual, we would just like to submit the following poll. And if you'd give that your kind attention, I'm sure the company would be most grateful. And I would now like to hand you over to the executive management team from HVIVO PLC. Moe, good evening, Good evening, I. Thanks for that. And welcome everyone to the HVIVO presentation for full year 2024. We're pleased to have you on board. This is our standard disclaimer as a publicly listed company. I'm Yami Mokhan. For those of you who don't know me, I've got over thirty years of experience working in the clinical research industry. I've been on board as CEO of HVIVO for just over, three years now, and I'm very pleased to be here. We'll jump, straight in, into our full year summary for 2024. So this slide shows our financial performance of the company, and it's been a record year for HVIVO and also a transformational one, with regards to operations. So we generated just under, £63,000,000 of revenue. That's a a 12% year on year growth, and a huge 60,000,000, EBITDA at a 26% margin. The underlying margin was, around 23% if you, took out the the facility fee, that we were offer...